Abstract
Candida auris is an emerging yeast pathogen of global significance. Its multidrug-resistant nature and inadequacies of conventional identification systems pose diagnostic and therapeutic challenges. This study investigated occurrence of C. auris in clinical specimens in Kuwait and its susceptibility to antifungal agents. Clinical yeast strains isolated during 3.5-year period and forming pink-colored colonies on CHROMagar Candida were studied by wet mount examination for microscopic morphology and Vitek 2 yeast identification system. A simple species-specific PCR assay was developed for molecular identification and results were confirmed by PCR-sequencing of rDNA. Antifungal susceptibility testing of one isolate from each patient was determined by Etest. The 280 isolates forming pink-colored colonies on CHROMagar Candida, were identified by Vitek 2 as Candida haemulonii (n = 166), Candida utilis (n = 49), Candida kefyr (n = 45), Candida guilliermondii (n = 9), Candida famata (n = 6) and Candida conglobata (n = 5). Species-specific PCR and PCR-sequencing of rDNA identified 166 C. haemulonii isolates as C. auris (n = 158), C. haemulonii (n = 6) and Candida duobushaemulonii (n = 2). C. auris isolates originated from diverse clinical specimens from 56 patients. Of 56 C. auris isolates tested, all were resistant to fluconazole, 41/56 (73%) and 13/56 (23%) were additionally resistant to voriconazole and amphotericin B, respectively. Eleven (20%) isolates were resistant to fluconazole, voriconazole and amphotericin B. One isolate was resistant to caspofungin and micafungin. Increasing isolation of C. auris in recent years from diverse clinical specimens including bloodstream shows that C. auris is an emerging non-albicans Candida species in Kuwait causing a variety of infections. Inability of conventional identification methods to accurately identify this pathogen and multidrug-resistant nature of many strains calls for a greater understanding of its epidemiology, risk factors for acquiring C. auris infection and management strategies in high-risk patients. This is the first comprehensive study on the emergence of this multidrug-resistant yeast from Kuwait and the Middle East.
Highlights
Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and is associated with high mortality [1,2,3,4]
AOnly selected isolates for these species were analyzed by PCR-sequencing of rDNA bAll six isolates identified as C. famata were correctly identified as C. fermentati by PCR-sequencing of rDNA
The PCR amplification performed with CAURF and CAURR primers yielded an expected size amplicon of nearly 276 bp with DNA extracted from the reference strain of C. auris only while no amplicon was obtained with genomic DNA prepared from reference strains or well characterized clinical isolates of C. dubliniensis, C. albicans, C. glabrata, C. parapsilosis, C. orthopsilosis, C. tropicalis, C. kefyr, C. utilis, C. guilliermondii, C. haemulonii, and C. duobushaemulonii, as expected (S1 Fig)
Summary
Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and is associated with high mortality [1,2,3,4]. Due to high mortality rates associated with C. auris infections in critically ill patients, this species is attracting worldwide attention as an opportunistic fungal pathogen [3, 7, 14]. 7 C. haemulonii strains that caused an outbreak in Maternity Hospital in Kuwait were identified in 2005–2006 [16] This retrospective study investigated the occurrence of C. auris among clinical yeast isolates forming pink-colored colonies on CHROMagar Candida that were recovered from diverse clinical specimens including bloodstream during a 3.5-year duration in Kuwait. Antifungal susceptibility testing of one isolate from each patient was determined
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.